Values First Advisors Inc. Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Values First Advisors Inc. bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,043 shares of the company’s stock, valued at approximately $93,000.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Revolution Medicines by 55.8% during the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after purchasing an additional 222 shares in the last quarter. Headlands Technologies LLC increased its holdings in Revolution Medicines by 140.9% during the first quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock worth $49,000 after buying an additional 885 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Revolution Medicines during the first quarter worth $104,000. EntryPoint Capital LLC acquired a new stake in Revolution Medicines in the first quarter valued at $107,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Revolution Medicines by 10.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock valued at $131,000 after acquiring an additional 320 shares during the period. 94.34% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RVMD has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Wedbush reaffirmed an “outperform” rating and issued a $59.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 8th. Barclays boosted their target price on Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, September 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $61.00 price target on shares of Revolution Medicines in a report on Thursday. Finally, Jefferies Financial Group initiated coverage on shares of Revolution Medicines in a report on Monday, July 8th. They issued a “buy” rating and a $63.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Revolution Medicines currently has an average rating of “Buy” and an average price target of $54.00.

Revolution Medicines Stock Performance

NASDAQ:RVMD opened at $46.42 on Friday. Revolution Medicines, Inc. has a 52 week low of $18.00 and a 52 week high of $51.00. The firm’s 50-day simple moving average is $45.19 and its 200 day simple moving average is $41.75. The firm has a market cap of $7.66 billion, a price-to-earnings ratio of -12.38 and a beta of 1.43.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, August 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.81 million. The company’s revenue for the quarter was down 73.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.92) earnings per share. Sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.35 EPS for the current year.

Insider Buying and Selling at Revolution Medicines

In other news, CFO Jack Anders sold 10,000 shares of the stock in a transaction on Friday, October 11th. The stock was sold at an average price of $50.30, for a total transaction of $503,000.00. Following the sale, the chief financial officer now directly owns 98,932 shares of the company’s stock, valued at approximately $4,976,279.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Revolution Medicines news, COO Margaret A. Horn sold 50,000 shares of the company’s stock in a transaction on Friday, October 11th. The stock was sold at an average price of $50.34, for a total transaction of $2,517,000.00. Following the completion of the sale, the chief operating officer now directly owns 132,320 shares in the company, valued at $6,660,988.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction on Friday, October 11th. The shares were sold at an average price of $50.30, for a total value of $503,000.00. Following the completion of the transaction, the chief financial officer now owns 98,932 shares in the company, valued at approximately $4,976,279.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 137,866 shares of company stock valued at $6,814,424 in the last three months. Corporate insiders own 8.00% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.